Tag Archive for: medical cannabis
ingredientpharm
ingredientpharmCannabis-Net meeting
ingredientpharm is hosting in a joint cooperation with University Hohenheim, Cannabis-Net Association, Glatt GmbH and Orocan AG the present Cannabis-Net meeting. From October 12th to 13th, international cannabis experts and project partners meet in Binzen, exchanging ideas and shaping the future of cannabis.
About Cannabis-Net
Cannabis-Net is a network platform for research institutions and companies in Germany and Canada. These work together to develop cannabis without narcotic suitability for the market. There are many open questions: How do which cannabis genetics thrive in the Central European climate? What are the options for drying the flowers and making them usable? And how can cannabis be harvested by the hectare?
About Orocan AG
Orocan is a Swiss based start-up company, serving qualitative CBD products to the European market. Products are water-dispersible solutions which daily dose can be simply added to food, meals and drinks. The range starts from single-dose units to larger sized bottles. All products are lab-controlled and made of trusted CBD from the EU.
About Glatt GmbH
Glatt is your exceptional partner for integrated process solutions for developing, processing and manufacturing powder solids. Develop powerful technologies, roll out innovative ideas, share our cumulative expertise worldwide – that is our mission. With integral solutions to make your business a success. As a pioneer in fluidized bed technology, we are now the partner to companies in the pharmaceutical, food, animal feed and fine chemicals industries. Glatt offers a unique portfolio of innovative products and extensive services to support your company across the entire process chain, including process development for new products and formulations, process technology, planning, right up to construction of the plant itself to manufacture your product.
About ingredientpharm
ingredientpharm is active in the field of functional excipients and food intermediates. In the field of Cannabis, ingredientpharm offers diverse CBD additives of different CBD concentrations for B2B businesses. These additives can be easily added in existing formulations in food, feed, cosmetic and pharmaceutical industry to quickly enter the growing market of cannabis products. All CBD products by ingredientpharm are free of THC (0.0% THC).
Tag Archive for: medical cannabis
Cannabis Health Symposium 2026
The Cannabis Health Symposium 2026 in Frankfurt offers a full‑day forum for clinicians, researchers, industry leaders and patient advocates. The meeting takes place on 4 November 2026 at Mainhaus and runs from 08:30 to 16:30. It focuses on Germany’s rapidly evolving medical cannabis landscape after the CanG reforms, which reshaped prescribing pathways, telemedicine access and patient demand.
The programme features twelve sessions and four panel debates, covering evidence, regulation, prescribing practice, pharmacy responsibilities, reimbursement challenges and public‑health insights. Speakers address the state of the German market, telemedicine debates, pharmaceutical quality standards, GMP and ASTM considerations, women’s health, chronic pain, mental health and European market comparisons.
The symposium attracts healthcare professionals, industry representatives and patient advocates, creating a multidisciplinary environment. Clinicians join to understand prescribing pathways, evidence and safeguards. Pharmacists attend to discuss product quality, substitution issues and evolving responsibilities. Industry leaders participate to explore competition, imports and regulatory trends. Researchers contribute public‑health data, including EKOCAN findings on cannabis reform.
Visitor numbers are not published, but the event targets Germany’s largest medical cannabis network and includes 12 months of MCCS membership, which signals strong professional engagement.
The symposium offers outstanding opportunities for networking and collaboration. Attendees gain direct access to decision‑makers shaping prescribing rules, telemedicine standards and pharmacy practice. Moreover, the event supports strategic dialogue between producers, distributors and regulators. As Germany’s market grows, participants can explore new business models, clinical pathways and quality frameworks. These discussions help align industry innovation with clinical needs and regulatory expectations.
Key industries represented include medical cannabis cultivation, pharmaceutical manufacturing, telemedicine providers, pharmacy networks, regulatory bodies and health‑data research. Their presence highlights the sector’s shift toward pharmaceutical rigor, digital access and evidence‑based policy. Together, these groups drive progress toward safer, standardized and accessible cannabinoid medicines in Germany.